[PDF][PDF] Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L
Y Urata, N Katakami, S Morita, R Kaji… - Journal of Clinical …, 2016 - clf1.medpagetoday.com
Purpose The epidermal growth factor receptor (EGFR) tyrosine kinase has been an
important target for non–small-cell lung cancer. Several EGFR tyrosine kinase inhibitors …
important target for non–small-cell lung cancer. Several EGFR tyrosine kinase inhibitors …
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L
Y Urata, N Katakami, S Morita, R Kaji… - Journal of Clinical …, 2016 - ascopubs.org
Purpose The epidermal growth factor receptor (EGFR) tyrosine kinase has been an
important target for non–small-cell lung cancer. Several EGFR tyrosine kinase inhibitors …
important target for non–small-cell lung cancer. Several EGFR tyrosine kinase inhibitors …
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
Y Urata, N Katakami, S Morita, R Kaji… - Journal of Clinical …, 2016 - europepmc.org
Purpose The epidermal growth factor receptor (EGFR) tyrosine kinase has been an
important target for non-small-cell lung cancer. Several EGFR tyrosine kinase inhibitors …
important target for non-small-cell lung cancer. Several EGFR tyrosine kinase inhibitors …
[PDF][PDF] Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L
Y Urata, N Katakami, S Morita, R Kaji, H Yoshioka… - J Clin …, 2016 - scholar.archive.org
Purpose The epidermal growth factor receptor (EGFR) tyrosine kinase has been an
important target for non–small-cell lung cancer. Several EGFR tyrosine kinase inhibitors …
important target for non–small-cell lung cancer. Several EGFR tyrosine kinase inhibitors …
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L
Y Urata, N Katakami, S Morita, R Kaji… - Journal of Clinical …, 2016 - cir.nii.ac.jp
< jats: sec>< jats: title> Purpose</jats: title>< jats: p> The epidermal growth factor receptor
(EGFR) tyrosine kinase has been an important target for non–small-cell lung cancer. Several …
(EGFR) tyrosine kinase has been an important target for non–small-cell lung cancer. Several …
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L
Y Urata, N Katakami, S Morita, R Kaji… - Journal of clinical …, 2016 - pubmed.ncbi.nlm.nih.gov
Purpose The epidermal growth factor receptor (EGFR) tyrosine kinase has been an
important target for non-small-cell lung cancer. Several EGFR tyrosine kinase inhibitors …
important target for non-small-cell lung cancer. Several EGFR tyrosine kinase inhibitors …
Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L
Y Urata, N Katakami, S Morita… - Journal of Clinical …, 2016 - kyushu-u.elsevierpure.com
Purpose: The epidermal growth factor receptor (EGFR) tyrosine kinase has been an
important target for non-small-cell lung cancer. Several EGFR tyrosine kinase inhibitors …
important target for non-small-cell lung cancer. Several EGFR tyrosine kinase inhibitors …